Shift of statin use towards the elderly in : a nation-wide register study in Finland
|
|
- Tracey Porter
- 5 years ago
- Views:
Transcription
1 British Journal of Clinical Pharmacology DOI:1.1111/j x Shift of statin use towards the elderly in : a nation-wide register study in Finland Päivi Ruokoniemi, 1,2,3 Arja Helin-Salmivaara, 1,2,4 Timo Klaukka, 5 Pertti J. Neuvonen 4 & Risto Huupponen 2,3 1 Graduate School of Clinical Drug Research, 2 Dept. of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland, 3 Clinical Pharmacology, Tykslab, Health Care District of Southwest Finland, Turku, Finland. 4 Dept. of Clinical Pharmacology, University of Helsinki, Helsinki, Finland, 5 Research Department, Social Insurance Institution, Helsinki, Finland Correspondence Dr Päivi Ruokoniemi MD, Department of Pharmacology, Drug Development and Therapeutics, University of Turku, FI-214 Turku, Finland Tel.: Fax: paivi.ruokoniemi@utu.fi Keywords hydroxymethylglutaryl-coa reductase inhibitors, incidence, prevalence, statins, utilization Received 4 January 28 Accepted 2 June 28 WHAT IS ALREADY KNOWN Statin use has increased in western societies since the 199s. Efficacy of statins in the prevention of coronary heart diseases has been clearly documented in the general population but only recently in elderly persons. WHAT THIS STUDY ADDS Since 1995 the use of statins has clearly shifted towards the elderly in Finland. At the beginning of the 11 year follow-up the prevalence of statin use was higher among males than females but since 22 the prevalence has been higher among females. AIM To describe nation-wide secular trends in statin use. METHODS Reimbursed prescriptions for lipid lowering drugs between 1995 and 25 in Finland were retrieved from the nation-wide Prescription Register. The 1 year prevalence and incidence of statin use stratified by gender and age of users were measured for each calendar year. The relative changes (RR) in the incidence and the prevalence were calculated by using the year 1995 as a reference. RESULTS The 1 year prevalence increased 11-fold (95% confidence interval 11.2, 11.5), i.e. from 7.8 per 1 inhabitants in 1995 to 88.9 in 25. The incidence increased five-fold (95% CI 4.9, 5.1) from 355 per 1 inhabitants to 1772 during the respective years. The prevalence and incidence were the highest among persons aged years. The largest relative increase in incidence was found among those aged 75 years, in both females (RR 14.1, 95% CI 13., 15.3) and males (RR 14., 95% CI 12.5, 15.7). Since 22 the prevalence has been higher among females (P <.5). CONCLUSIONS As statin use has increased particularly among the elderly, further studies on the benefits in real life situation are needed in this age group. 28 The Authors Journal compilation 28 Blackwell Publishing Ltd Br J Clin Pharmacol / 66:3 / / 45
2 P. Ruokoniemi et al. Introduction The use of lipid-lowering drugs (LLDs), mainly 3-hydroxy- 3-methylglutaryl coentzyme A reductase inhibitors (statins) has increased exponentially in western societies [1, 2] since the publication of the Scandinavian Simvastatin Survival Study (4S) in 1994 [3]. Publication of other benchmarking trials in the late 199s [4 6] further stimulated the use. The increase has been seen in pharmacy based registers [7 9], surveys [1, 11] and administrative databases [8, 12 16] including drug consumption statistics [17]. Despite the increase in statin use, data on its prevalence, and especially on new users categorized by the demographic characteristics are scarce in general population [2, 9, 13 15]. Furthermore, the generalizability of previous utilization studies is limited due to the small size or restrictions of the study populations, or the time windows included in the studies: most of them describe statin use during the 199s. As in other western societies, statin use in Finland has also increased exponentially [17]. In 25 the total consumption was 94.9 defined daily doses (DDD) per 1 inhabitants a day [18]. Simvastatin has been the most used statin since 1997; in 25 it accounted for 4% of statin consumption [18]. The use of atorvastatin has steadily increased since its introduction in 1998, and atorvastatin accounted for 34% of statin consumption in 25. Rosuvastatin, pravastatin, fluvastatin and lovastatin are clearly smaller players in the market, each of them accounting for less than 1% of the consumption [18]. The comprehensive nation-wide drug reimbursement registers make Finland suitable for studies on drug utilization patterns.the aim of the present study was to evaluate the use of statin therapy in the Finnish population between the years 1995 and 25. We analyzed trends of prevalence and incidence of statin use separately for both genders in various age categories. Methods Data source The data were based on the national Prescription Register managed by the Social Insurance Institution. All permanent residents living in community are included in the Register. In 23, 94.6% of the consumption for lipid lowering drugs (consisting mainly statins) outside institutions was covered by the Register (Martikainen J, the Social Insurance Institution, personal information). In this study a prescription refers to the amount of reimbursable medicine which consists of one preparation purchased during one transaction from a pharmacy. Reimbursed medicines can be supplied to a patient for no longer than 3 months per purchase. Consequently, a 1 year therapy issued by a physician contributes at least four prescriptions. The reimbursement register covers purchases that meet the minimum deductible limit, i.e euros until 22 and 1 euros thereafter until 26. All statins are available on prescription only. During the study period all statin prescriptions were reimbursable, and with a minor exception their purchases were also registered. After the introduction of generic substitution in 23 a limited number of lowprice simvastatin packages remained below the deductible limit in and were registered only if the patient purchased other reimbursable medicines at the same transaction. The data on the population were collected by the Social Insurance Institution. During the study period the population increased from 5.1 to 5.3 million. Prescriptions The following LLD prescriptions were retrieved using the corresponding Anatomical Therapeutic Chemical code (ATC) presented by the WHO [19]: simvastatin (C1AA1), lovastatin (C1AA2), pravastatin (C1AA3), fluvastatin (C1AA4), atorvastatin (C1AA5), cerivastatin (C1AA6), rosuvastatin (C1AA7), clofibrate (C1AB1), bezafibrate (C1AB2), gemfibrozil (C1AB4), fenofibrate (C1AB5), cholestyramine (C1AC1), colestipol (C1AC2) and ezetimibe (C1AX9). These ATC codes were applied for the years between 1996 and 25 [19].For the years 1994 and 1995 respective ATC codes valid for that time were used [2]. The LLD users were identified by a unique social security number linked to each prescription in the register. Reimbursed LLD prescriptions were further linked with the date of the purchase, the gender and the age of the patient in years at the end of each calendar year. Definitions The 1 year period prevalence of statin use was calculated from the number of persons who redeemed at least one reimbursed statin prescription during a calendar year divided by the number of inhabitants in Finland at the end of the respective year. The 1 year incidence of statin use was defined as the number of initiators, new users in the respective year divided by the number of inhabitants excluding those who had redeemed at least one statin prescription during the previous year. The prescription data in 1994 were used to ensure that new users of statins in 1995 had not redeemed any statins during the previous year. The genders were analyzed separately. Both the prevalence and the incidence were calculated for patients aged 44 years or less, for those aged 45-54, 55-64, and 75 years or more.the age and gender specific population was used in the denominator where appropriate. Statistical analysis To analyze the relative changes in statin use, the rate ratios (RR) of the 1 year prevalence in each year in relation to the reference year 1995 and the respective RRs of incidences and their 95% confidence intervals were calculated using 46 / 66:3 / Br J Clin Pharmacol
3 Statin use Table 1 1 year prevalence of statin use (at least one reimbursed statin prescription per year); users per 1 inhabitants in Finland and the median age of all users in respective years Both genders Males* Females* Median age, year (interquartile range) (54 68) (55 69) (56 7) (56 7) (56 71) (56 72) (56 72) (57 73) (57 73) (57 73) (57 74) *The difference between males and females P <.5 in all other years but in 2 and 21. Users/1 male inhabitants Users/1 female inhabitants 4 A B the Poisson regression. A two-tailed P value <.5 was regarded as statistically significant. The crude prevalence and incidence in each year were standardized according to the age and gender specific population in 2.The statistical analyses were performed using SAS version 9.1 (SAS Institute Inc., Cary, NC). Results After the exclusion of persons with incomplete data (n = 16) a total of persons who had received at least one prescription for a LLD were identified. Among these, persons received at least one prescription for a statin. The number of statin users increased from 4 89 (.8% of the population) in 1995 to (8.9%) in 25. The number of users of other LLDs than statins decreased slightly from 846 to 7314 during the respective years. In the following only data on statins are presented. The median age of the users increased from 62 to 66 years during the 11 year observation period (Table 1). Among the users in 25 ( persons) the largest group was males younger than 65 years who accounted for 33.3% of the users, and the second largest group was females 65 years of age with the 26.5% share. Prevalence The 1 year prevalence of statin use increased from 7.8 per 1 inhabitants in 1995 to 88.9 in 25 (RR 11.3, 95% CI 11.2, 11.5). Among females, the prevalence increased from 6.9 per 1 female inhabitants to 89.3, and among males from 8.8 to 88.5 per 1 male inhabitants during the respective years (Table 1). From 1995 to 1999 the prevalence of statin use was significantly higher among males Figure 1 1 year prevalence of statin use stratified by age among males (A) and females (B) in Finland. >75 years ( ); years ( ); years ( ); years ( ); <44 years ( ) than among females (P <.5) but since 22 the situation has reversed: the prevalence was higher among females (P <.5). The direct standardization procedure according to the population in 2 did not affect the results and hence the crude period prevalence is presented (Table 1, Figure 1). Among both genders the prevalence increased in all age categories during the 11 year follow-up (Figure 1).The relative increase was most prominent among those aged at least 75 years (RR 4.6, 95% CI 37.5, 43.9 for males and RR 4.2, 95% CI 38.1, 42.4 for females). The gender specific 1 year prevalence in this age category increased from 7. per 1 male inhabitants in 1995 to in 25 and from 6.7 per 1 female inhabitants to 264.4, respectively. Incidence The overall incidence of statin use increased from 355 per 1 inhabitants in 1995 to 1772 in 25 (RR 5., 95% CI 4.9, 5.1). Among females, the incidence increased from 312 per 1 female inhabitants to 1732, and among males from 399 to 1815 per 1 male inhabitants. In 1995 the 1 year incidence was higher among males than females (RR 1.3, 95% CI 1.2, 1.3) but since 1996 no significant difference was observed. Persons aged between 65 and 74 years showed the highest incidence in both genders over the whole observation period (Figure 2). Direct standardization to the year 2 population did not significantly affect the incidence figures either. Br J Clin Pharmacol / 66:3 / 47
4 P. Ruokoniemi et al. New users/1 male inhabitants New users/1 female inhabitants Figure 2 A In concordance with prevalence, the relative increase in the number of new users was the highest among persons aged at least 75 years (RR 14., 95% CI 12.5, 15.7 for male users and RR 14.1, 95% CI 13., 15.3 for female users). The increase in the incidence among the oldest persons was from 353 per 1 male inhabitants in 1995 to 4948 in 25, and from 31 per 1 female inhabitants to 4 252, respectively. All values for prevalence and incidence for both genders in various age categories are presented in the electronic supplementary data online. Discussion B year incidence of statin use stratified by age among males (A) and females (B) in Finland. >75 years ( ); years ( ); years ( ); years ( ); <44 years ( ) Among the whole population of Finland the relative increase of the prevalence of statin use was 11-fold between 1995 and 25. The most evident, 4-fold, increase was observed among persons aged at least 75 years. The relative increase of the incidence was five-fold among the whole population. In accordance with the highest relative change of the prevalence, the largest (14- fold) increase of the incidence was observed among the oldest persons. In absolute terms, both the highest prevalence and incidence of statin use were found among persons aged between 65 and 74 years; 31% of the persons in this age category had used statins in 25. Only small differences in the statin use between the genders were found. The Prescription Register covers every permanent resident of Finland receiving statin treatment in open care. The further strength of our study was the low turnover of the population. However, persons staying permanently in public institutional care are not entitled to drug reimbursement, and were thus not included in our study. Therefore, we may have underestimated statin use especially among the elderly.furthermore, the Prescription Register does not cover non-reimbursed medicines of low-price packages. During all statin prescriptions were registered, but after the introduction of generic substitution in 23 prices of a limited number of simvastatin packages fell below the reimbursement level in Thus, the plateau observed in the incidence level in 25 may be more of a reflection of the decreased coverage of statins in the Register than a real decrease in the number of new users. The observed increase in prevalence among those aged at least 75 years partly reflects a continuum of statin therapy initiated at earlier ages. However, the relative increase in the number of new users among the oldest population, already observed during the 199s, is concordant with the transition of coronary heart disease (CHD) prevalence towards the oldest group. In Finland the prevalence of CHD has decreased among persons younger than 65 years, and increased during the past 2 years among those aged more than 75 years [21]. Consequently, in 2 the most dominant group of patients with CHD was females aged 75 years [21]. The increase in the prevalence of statin use also reflects the increase in the morbidity of CHD. The ageing of the Finnish population has promoted the increase in the total estimated number of persons with established CHD by 18% during the past 2 years [21] although the incidence of first myocardial infarction (MI) decreased between 1991 and 21 [22]. The reduction in MI incidence and the shift of CHD morbidity towards those aged over 75 years suggests successful primary prevention among the younger population. Large statin trials conducted during the 199s showed clear evidence on statin efficacy in the prevention of CHD events [3 6]. These trials were not specifically conducted among the elderly though data from sub-analyses revealed efficacy of statin treatment also among those aged up to 75 years [3, 5]. The first trials showing efficacy among persons aged over 75 years were not published until 22 [23, 24] and the respective recommendations were incorporated into the Finnish evidence-based clinical guidelines on dyslipidaemia 2 years later [25]. Thus, the clinical trial evidence on the younger population present in the 199s may have already been extrapolated to elderly patients by physicians before 22. A cross-sectional survey conducted among Finns in 2 showed that the percentage of males with CHD or with low density lipoprotein values higher than 3. mmol l 1 (116 mg dl 1 ) was significantly higher than 48 / 66:3 / Br J Clin Pharmacol
5 Statin use that for females [26]. Hence, we assumed that males would use statins more frequently than females, but after 1999 no remarkable gender differences in prevalence existed (Table 1). The slopes of the incidence curves were steepest in 1998/1999 and 23/24 (Figure 2). These coincide with, and may be explained by, the launching of atorvastatin in 1998 onto the Finnish market and the introduction of generic substitution in 23. The intensive marketing of atorvastatin may have targeted therapy to persons not previously considered eligible for statins. On the other hand, the substantial price reductions of generic simvastatin and other generic statin preparations may have boosted their use. The direct comparison of our results with other studies is difficult since only a few studies have used similar methodology to describe the demographics of statin users. In Norway, the 1 year prevalence of statin use among males was 7.5% and among females 6.3% in 24/25 [27]. Furthermore, national statistics on drug use in other Nordic countries offer relevant comparison data [28, 29]. In Sweden the intensity of statin use among females counted by DDDs was 27% lower than among males, and in Denmark 46% of the users were females. The use was the most intensive among persons aged years in Sweden. In Denmark the median age of the users was 2 years lower than in Finland, 64 years (interquartile range 57-72) in 25 [29]. The prevalence and incidence figures on statin use in our study corresponded to the highest prevalence and incidence of the use of all lipid lowering drugs among populations aged 6-69 years in some previous studies [14, 15]. A previous report from Finland [8], as well as reports from Sweden [12], Denmark [2, 13, 15] and the Netherlands [14] have shown increasing LLD use in the 199s to be dominated by males. In conclusion, in Finland the use of statins had already shifted to elderly persons some years before rigorous evidence from clinical trials was available. The shift was in accordance with the change in the age-specific prevalence of CHD. However, current targeting of statin therapy may be partly suboptimal as reflected by the missing difference in the utilization pattern between the genders. Considering the large number of the elderly, a fragile population, continuously on statins studies on benefits and harms in a real-life setting among elderly are needed. Disclosures: Päivi Ruokoniemi: No conflict of interests. Arja Helin-Salmivaara: No conflict of interests. Timo Klaukka: No conflict of interests. Pertti J. Neuvonen: No conflict of interests. Risto Huupponen: No conflict of interests. We thank Hilkka Ruuska and Kristiina Tyrkkö, from the Social Insurance Institution, for their data management skills and biostatistician Tero Vahlberg, Department of Biostatistics, University of Turku, for his valuable instructions and comments on statistical analysis. This study was partly funded by the research grant from the Social Insurance Institution (1/26/27). The sponsor had no role in the design, conduct, analysis, interpretation of the data, or in the preparation, review, or approval of the manuscript. REFERENCES 1 Baxter C, Jones R, Corr L. Time trend analysis and variations in prescribing lipid lowering drugs in general practice. BMJ 1998; 317: Larsen J, Andersen M, Kragstrup J, Gram LF. Changes in the utilisation of lipid-lowering drugs over a 6-year period ( ) in a Danish population. Eur J Clin Pharmacol 21; 57: Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E for the Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: Siegel D, Lopez J, Meier J. Use of cholesterol-lowering medications in the United States from 1991 to Am J Med 2; 18: Martikainen J, Klaukka T, Reunanen A, Peura S, Wahlroos H. Recent trends in the consumption of lipid-lowering drugs in Finland. J Clin Epidemiol 1996; 49: Deambrosis P, Saramin C, Terrazzani G, Scaldaferri L, Debetto P, Giusti P, Chinellato A. Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period Eur J Clin Pharmacol 27; 63: Wang TJ, Stafford RS, Ausiello JC, Chaisson CE. Randomized clinical trials and recent patterns in the use of statins. Am Heart J 21; 141: EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 21; 357: Br J Clin Pharmacol / 66:3 / 49
6 P. Ruokoniemi et al. 12 Magrini N, Einarson T, Vaccheri A, McManus P, Montanaro N, Bergman U. Use of lipid-lowering drugs from 199 to 1994: an international comparison among Australia, Finland, Italy (Emilia Romagna Region), Norway and Sweden. Eur J Clin Pharmacol 1997; 53: Larsen J, Vaccheri A, Andersen M, Montanaro N, Bergman U. Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy. Br J Clin Pharmacol 2; 49: Mantel-Teeuwisse AK, Klungel OH, Verschuren WM, Porsius AJ, de Boer A. Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated? Br J Clin Pharmacol 22; 53: Riahi S, Fonager K, Toft E, Hvilsted-Rasmussen L, Bendsen J, Paaske Johnsen S, Sorensen HT. Use of lipid-lowering drugs during in Northern Jutland, Denmark. Br J Clin Pharmacol 21; 52: Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe Br J Clin Pharmacol 25; 6: Nordic Medico Statistical Committee (Nomesco). Medicines Consumption in the Nordic Countries Copenhagen, Denmark: Nomesco, The National Agency for Medicines and the Social Insurance Institution. Finnish Statistics on Medicines 25. Helsinki, Finland: National Agency for Medicines and the Social Insurance Institution, The National Agency for Medicines. Classification of Medicines and the Defined Daily Doses 25. Helsinki, Finland: National Agencies for Medicines, The National Agency for Medicines. Classification of Medicines and the Defined Daily Doses Helsinki, Finland: National Agencies for Medicines, Kattainen A, Salomaa V, Härkänen T, Jula A, Kaaja R, Kesäniemi YA, Kähönen M, Moilanen L, Nieminen MS, Aromaa A, Reunanen A. Coronary heart disease: from a disease of middle-aged men in the late 197s to a disease of elderly women in the 2s. Eur Heart J 26; 27: Pajunen P, Pääkkönen R, Juolevi A, Hämäläinen H, Keskimäki I, Laatikainen T, Moltchanov V, Niemi M, Rintanen H, Salomaa V. Trends in fatal and non-fatal coronary heart disease events in Finland during Scand Cardiovasc J 24; 38: Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RGJ. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 22; 36: Heart protection Study Collaborative Group. MRC/BHF heart Protection Study of cholesterol lowering with simvastatin in high-risk individuals: a randomised placebo-controlled trial. Lancet 22; 36: Suomen Sisätautilääkärien yhdistyksen asettama työryhmä. Dyslipidemiat. Duodecim 24; 12: (in Finnish). 26 Aromaa A, Koskinen S. Health and functional capacity in Finland. Baseline results of the Health 2 health examination survey. Publications of the National Public Health Institute 22; B3/ Sakshaug S, Furu K, Karlstad Ø, Rønnig M, Skurtveit S. Switching statins in Norway after new reimbursement policy a nationwide prescription study. Br J Clin Pharmacol 27; 64: Försäljningsstatistik. Statistics on medicinal product sales. Available at VadViGor/Forsalj/default.htm (last accessed 3 August 27). 29 Danish Medicines Agency. Medicinal Product Statistics Danish Medicines Agency, Denmark: Legemiddelstyrelsen, 26. Supporting information Additional supporting information may be found in the online version of this article: Table S1 1 year prevalence of statin use, both genders (per 1) Table S2 1 year prevalence of statin use among males (per 1) Table S3 1 year prevalence of statin use among females (per 1) Table S4 1 year incidence of statin use, both genders (per 1 ) Table S5 1 year incidence of statin use among males (per 1 ) Table S6 1 year incidence of statin use among females (per 1 ) Please note: Blackwell Publishing is not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article. 41 / 66:3 / Br J Clin Pharmacol
Aspects of statin prescribing in Norwegian counties with high, average and low statin. Department of Pharmacy, University of Tromsø, Tromsø, Norway
Title page Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individualised prescription database study Ingeborg Hartz, 1 Solveig Sakshaug, 2 Kari Furu
More informationAPPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More informationLack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in de ned populations in Funen, Denmark and Bologna, Italy
Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in de ned populations in Funen, Denmark and Bologna, Italy John Larsen, 1,2 Alberto Vaccheri, 3 Morten Andersen,
More informationData Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association
More informationNew Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines
Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular
More informationThe implications of a growing evidence base for drug use in elderly patients. Part 1. Statins for primary and secondary cardiovascular prevention
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2006.02609.x The implications of a growing evidence base for drug use in elderly patients. Part 1. Statins for primary and secondary cardiovascular
More informationCost effectiveness of statin therapy for the primary prevention of coronary heart disease in Ireland Nash A, Barry M, Walshe V
Cost effectiveness of statin therapy for the primary prevention of coronary heart disease in Ireland Nash A, Barry M, Walshe V Record Status This is a critical abstract of an economic evaluation that meets
More informationPEER REVIEW HISTORY ARTICLE DETAILS VERSION 1 - REVIEW. Randi Selmer Senior Researcher Norwegian Institute of Public Health Norway
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (see an example) and are provided with free text boxes to
More informationThe All Wales Medicine Strategy Group (AWMSG) is asked to support implementation of the following prescribing indicators.
ENCLOSURE 5 APPENDIX 1 Paper presented to AWMSG in June 2006 AWPAG considered comments recorded in AWMSG minutes in July 2006 Paper subsequently updated and brought back to AWMSG for endorsement This paper
More informationBRAGE Hedmark University College s Open Research Archive
Faculty of Health and Sports BRAGE Hedmark University College s Open Research Archive http://brage.bibsys.no/hhe/ This is the author s version of the article published in European journal of clinical pharmacology
More informationStatin Use and Risk of Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders
Statin Use and Risk of Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders Henrik Toft Sørensen, DMSc; Anders Hammerich Riis, MSc; Timothy L. Lash, DSc; Lars Pedersen, PhD Background Use of
More informationStatins and newly diagnosed diabetes
DOI:10.1111/j.1365-2125.2004.02142.x British Journal of Clinical Pharmacology Statins and newly diagnosed diabetes Susan S. Jick & Brian D. Bradbury Boston Collaborative Drug Surveillance Program, 11 Muzzey
More informationThreshold Level or Not for Low-Density Lipoprotein Cholesterol
... SYMPOSIA PROCEEDINGS... Threshold Level or Not for Low-Density Lipoprotein Cholesterol Based on a debate between Philip J. Barter, MD, PhD, FRACP, and Frank M. Sacks, MD Debate Summary As drugs, such
More informationInfluences of Statins on Glucose Tolerance in Patients with Type 2 Diabetes Mellitus
Original Article 95 Influences of Statins on Glucose Tolerance in Patients with Type 2 Diabetes Mellitus Tatsuro Takano, Tadashi Yamakawa, Mayumi Takahashi, Mari Kimura, and Atsushi Okamura Department
More informationReducing low-density lipoprotein cholesterol treating to target and meeting new European goals
European Heart Journal Supplements (2004) 6 (Supplement A), A12 A18 Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals University of Sydney, Sydney, NSW, Australia
More informationClinical research. Ingeborg Hartz 1 *, Inger Njølstad 2, and Anne Elise Eggen 1. Introduction
European Heart Journal (2005) 26, 2673 2680 doi:10.1093/eurheartj/ehi556 Clinical research Does implementation of the European guidelines based on the SCORE model double the number of Norwegian adults
More informationOutline. Definitions. ATC Anatomical Therapeutic Chemical classification
The Anatomical Therapeutic Chemical Classification and the Defined Daily Dose: Classifying and Quantifying Drug Use Hanne Strøm Department of Pharmacoepidemiology ICPE, Chicago August 2011 : Preconference
More information( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationThe treatment of coronary heart disease (CHD) The Health Economics of the Treatment of Hyperlipidemia and Hypertension J. McMurray
AJH 1999;12:99S 104S The Health Economics of the Treatment of Hyperlipidemia and Hypertension J. McMurray In the current economic climate it is important to demonstrate that healthcare resources are being
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationPrescribing behaviour according to Dutch and European guidelines on the management of hypercholesterolaemia ( )
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2006.02634.x Prescribing behaviour according to Dutch and European guidelines on the management of hypercholesterolaemia (1992 1999) Aukje
More informationStatins in the elderly: What evidence of their benefit in prevention?
Archives of Cardiovascular Disease (2010) 103, 61 65 SCIENTIFIC EDITORIAL Statins in the elderly: What evidence of their benefit in prevention? Les statines chez les personnes âgées : quelle preuve de
More informationA bs tr ac t. n engl j med 357;15 october 11,
The new england journal of medicine established in 1812 october 11, 2007 vol. 357 no. 15 Long-Term Follow-up of the West of Scotland Coronary Prevention Study Ian Ford, Ph.D., Heather Murray, M.Sc., Chris
More informationFaculty of Health and Sports BRAGE. Hedmark University College s Open Research Archive
Faculty of Health and Sports BRAGE Hedmark University College s Open Research Archive http://brage.bibsys.no/hhe/ This is the author s version of the article published in Scandinavian Journal of Primary
More informationCoronary artery disease remains the leading
UNMET NEEDS IN THE TREATMENT OF ATHEROSCLEROSIS: WHY ARE WE NOT DONE YET? * Evan A. Stein, MD, PhD ABSTRACT Heart disease remains the leading cause of death in the United States. Despite advances in surgical,
More informationAcute myocardial infarction incidence and hospital mortality: routinely collected national data versus linkage of national registers
Eur J Epidemiol (2007) 22:755 762 DOI 10.1007/s10654-007-9174-6 CARDIOVASCULAR DISEASE Acute myocardial infarction incidence and hospital mortality: routinely collected national data versus linkage of
More informationC oronary heart disease (CHD) is a leading cause of morbidity
229 CARDIOVASCULAR MEDICINE Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study L Wei, J Wang, P Thompson, S Wong, A D Struthers, T M MacDonald...
More informationrosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd.
rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationComments from AstraZeneca UK Ltd
13 June 2007 NICE HTA: Ezetimibe for the treatment of primary (heterozygous familial and nonfamilial) hypercholesterolemia Appraisal Consultation Document (ACD) Many thanks for providing the ACD for the
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationDiscontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database
open access Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database Yana Vinogradova, 1 Carol Coupland, 1 Peter Brindle, 2,3 Julia Hippisley-Cox
More informationStatins in the elderly : Is there a rationale?
Statins in the elderly : Is there a rationale? Pr B Boland After a communication by Dr. Manfred Gogol EAMA, Sion, June, 2006 1 RCTs with Statins Meta-Analysis, 1999 182 abstracts or research papers 29
More informationCite this article as: BMJ, doi: /bmj f (published 24 March 2005)
Cite this article as: BMJ, doi:10.1136/bmj.38398.408032.8f (published 24 March 2005) Primary care Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationEffect of statins on the mortality of patients with ischaemic heart disease: population based cohort study with nested case control analysis
752 CARDIOVASCULAR MEDICINE Effect of statins on the mortality of patients with ischaemic heart disease: population based cohort study with nested case control analysis J Hippisley-Cox, C Coupland... Heart
More informationRepeated dispensing of codeine is associated with high consumption of benzodiazepines
Norsk Epidemiologi 2008; 18 (2): 185-190 185 Repeated dispensing of codeine is associated with high consumption of benzodiazepines Liliana C. Bachs 1, Jørgen G. Bramness 2, Anders Engeland 2,3 and Svetlana
More informationThesis for the degree of Doctor Scientarium. A pharmacoepidemiological study of lipid-lowering drugs in Norway
Thesis for the degree of Doctor Scientarium A pharmacoepidemiological study of lipid-lowering drugs in Norway Ingeborg Hartz 2006 Department of Pharmacoepidemiology and Pharmacy Practice Institute of Pharmacy,
More informationPeriodic Rosuvastatin or Atorvastatin Dosing Arrays (PRADA): Patient-Centered Practice
Drugs R D (2014) 14:221 225 DOI 10.1007/s40268-014-0061-9 ORIGINAL RESEARCH ARTICLE Periodic Rosuvastatin or Atorvastatin Dosing Arrays (PRADA): Patient-Centered Practice Theodore Christou Hesham R. Omar
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationStatins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. C ANYANWU, C NOSIRI Citation C ANYANWU, C NOSIRI.
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationSOLVAY GROUP London Morning Meeting. June 26, 2009
SOLVAY GROUP London Morning Meeting June 2, 9 1 Our fenofibrate franchise Klaus Kirchgassler, MD Sr VP Solvay Pharmaceuticals 2 Summary of lipid lowering market performance in Value Growth vs. previous
More informationCoronary heart disease prevention and age inequalities:
Coronary heart disease prevention and age inequalities: the first year of the National Service Framework for CHD Julia Hippisley-Cox, Michael Pringle, Ruth Cater, Carol Coupland and Andy Meal ABSTRACT
More informationUpdated cost utility analysis for statins
Updated cost utility analysis for statins Scott Metcalfe Pharmac 30 January 2001 Pharmac estimates the cost-utility of providing statins to everyone with dyslipidaemia and > 10% 5-year absolute risk of
More informationSetting Community. The economic study was carried out in Cambridge, United Kingdom.
Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population Pharoah
More informationPRESCRIBING INDICATORS UPDATED FEBRUARY 2010
PRESCRIBING INDICATORS 2010-11 UPDATED FEBRUARY 2010 This paper sets out the proposed national prescribing indicators for 2010/11 retaining efficiency and safety principles as a means to monitor Local
More informationCLINICAL. Determinants of Compliance With Statin Therapy and Low-Density Lipoprotein Cholesterol Goal Attainment in a Managed Care Population
Determinants of Compliance With Statin Therapy and Low-Density Lipoprotein Cholesterol Goal Attainment in a Managed Care Population Jennifer S. Schultz, PhD; John C. O Donnell, PhD; Ken L. McDonough, MD;
More informationLIST OF ABBREVIATIONS
Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,
More informationHealth Checkup for the Elderly in the St. Marianna University School of Medicine Hospital
531 Original Article St. Marianna Med. J. Vol. 36, pp. 531536, 2008 Health Checkup for the Elderly in the St. Marianna University School of Medicine Hospital Yuko Tohyo 1, Masatoshi Hara 1,KaeSuzuki 1,
More informationThe important role of cholesterol in the development
Research Recherche The use of cholesterol-lowering medications after coronary revascularization James M. Brophy, Chantal Bourgault, Paul Brassard Abstract Background: In clinical trials, cholesterol-lowering
More informationManaged Care Trends in Statin Usage GARY R. BAZALO, MS, MBA
PHARMACY UTILIZATION Managed Care Trends in Statin Usage GARY R. BAZALO, MS, MBA ABSTRACT Purpose HMG-CoA reductase inhibitors ( statins ) have become the drug class of choice for the treatment of hyperlipidemia.
More informationAn example of a systematic review and meta-analysis
An example of a systematic review and meta-analysis Sattar N et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742. Search strategy
More informationFrequency of Simvastatin Prescriptions With Potentially Interacting Medications in a Veterans Affairs Health Care System
ORIGINAL RESEARCH Frequency of Simvastatin Prescriptions With Potentially Interacting Medications in a Veterans Affairs Health Care System JERILYN B. PETROPOULOS, BSPharm, PharmD, BCPS, and CRISTINA E.
More informationDrug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin
Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin Final Report Update 5 November 2009 This report reviews information about the comparative
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationStatins and stroke prevention
Acta neurol. belg., 2003, 103, 13-18 Statins and stroke prevention P. LALOUX Service de Neurologie, Cliniques Universitaires de Mont-Godinne, Université Catholique de Louvain, Yvoir, Belgium Key words
More informationStatin adherence and the risk of major coronary events in patients with diabetes: a nested case control study
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2010.03895.x Statin adherence and the risk of major coronary events in patients with diabetes: a nested case control study Päivi Ruokoniemi,
More informationPlasma lipids and cardiovascular risk: a POSCH report
Atherosclerosis 154 (2001) 221 227 www.elsevier.com/locate/atherosclerosis Plasma lipids and cardiovascular risk: a POSCH report Henry Buchwald a, *, James R. Boen b, Phuong A. Nguyen a, Stanley E. Williams
More informationUCC Library and UCC researchers have made this item openly available. Please let us know how this has helped you. Thanks!
UCC Library and UCC researchers have made this item openly available. Please let us know how this has helped you. Thanks! Title Author(s) Long-term effects of statin treatment in elderly people: extended
More informationSupplementary Online Content
Supplementary Online Content Gutierrez J, Ramirez G, Rundek T, Sacco RL. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med. 2012;172(12):IRA120005.
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Olesen JB, Lip GYH, Kamper A-L, et al. Stroke and bleeding
More informationCost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T
Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T Record Status This is a critical abstract of an economic evaluation
More informationThe role of statins in patients with arterial hypertension
Invited review The role of statins in patients with arterial hypertension Trygve B. Tjugen 1, Sigrun Halvorsen 1, Reidar Bjørnerheim 1, Sverre E. Kjeldsen 1, 2 1University of Oslo, Department of Cardiology,
More informationSetting The setting was primary care. The economic study was carried out in the UK.
Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK Davies A, Hutton J, O'Donnell J, Kingslake S Record Status This is
More informationStatins reduce the incidence of coronary events in patients
Comments, Opinions, and Reviews Statin Therapy for Stroke Prevention Abdullah Nassief, MD; James D. Marsh, MD Background and Purpose Statins are widely used to reduce the risk of stroke in patients with
More informationOriginal paper. Abstract. Abdullah S. Asia 1*, Al-Mahdi A. Modar 2, Hadi M. Ali 3
Original paper Frequency Of Potential Adverse Effects Of A Semisynthetic Statin (Simvastatin) Compared To A Synthetic Statin (Atorvastatin) Used To Reduce Cardiovascular Risk For Patients In Basra 1*,
More informationStatins for primary and secondary prevention in the oldest old: an overview of the existing. evidence. Werbrouck B., Van Den Noortgate N., Petrovic M.
Statins for primary and secondary prevention in the oldest old: an overview of the existing evidence Werbrouck B., Van Den Noortgate N., Petrovic M. Service of Geriatrics, Ghent University Hospital, De
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:
More informationCHOLESTEROL-LOWERING THERAPHY
CHOLESTEROL-LOWERING THERAPHY TRIALS NUMBER OF PARTICIPANTS NUMBER OF WOMEN PERCENTAGE OF WOMEN MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 50,194 15,036 30.0% 60.8 3.2 1/ 6 (16.7%) HR
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationCardiovascular disease (CVD) is the
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Cost Effectiveness of Statin Therapy for the Primary Prevention of Major Coronary Events in Individuals With Type 2 Diabetes
More informationTailored Statin Treatment for Type 2 Diabetes. Han, Ki Hoon Asan Medical Center University of Ulsan
Tailored Statin Treatment for Type 2 Diabetes Han, Ki Hoon Asan Medical Center University of Ulsan 1 Cardiovascular disease ; No1. death (2001) respiratory tract infection Other NCD S HIV/AIDS deaths during
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationMeta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes
et al. British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2003.02060.x Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes Bernard
More informationKanyini Guidelines Adherence with the Polypill (Kanyini GAP)
Kanyini Guidelines Adherence with the Polypill (Kanyini GAP) Disclosures Funded by the National Health and Medical Research Council of Australia. Dr Reddy s Laboratories Ltd manufactured and supplied polypills
More informationSupplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction
Supplement: Tables Supplement Table 1. Study Eligibility Criteria Supplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction Supplement Table
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationCoronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol)
CLINICAL GUIDELINE Coronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol) A guideline is intended to assist healthcare professionals in the choice of disease-specific
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationCalculating RR, ARR, NNT
Calculating RR, ARR, NNT In a trial RR = Event rate (eg # of people with one stroke/ total people) in treatment group/event rate in the control group. ARR = Event rate in control group minus the event
More informationUsing routinely collected clinical data to support Clinical Trials: a view from Scotland
Using routinely collected clinical data to support Clinical Trials: a view from Scotland Professor Colin McCowan Robertson Centre for Biostatistics and Glasgow Clinical Trials Unit From birth to death
More informationSee p Downloaded from by on January 18, 2019 The beneficial effects of cholesterol-lowering therapy for the
Relationship Between Plasma LDL Concentrations During Treatment With Pravastatin and Recurrent Coronary Events in the Cholesterol and Recurrent Events Trial Frank M. Sacks, MD; Lemuel A. Moyé, MD, PhD;
More informationImpact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review
British Journal of Clinical Pharmacology DOI:10.1111/bcp.12339 Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review Mary A. De Vera, 1,2 Vidula Bhole, 2 Lindsay
More informationnicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck
Scottish Medicines Consortium Resubmission nicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck New formulation 6 January 2006 The Scottish Medicines Consortium
More informationStatin use and risk of endometrial cancer: a nationwide registry-based case control study
AOGS ORIGINAL RESEARCH ARTICLE : a nationwide registry-based case control study CECILIE D. SPERLING 1, FREIJA VERDOODT 1, SØREN FRIIS 2,3,4, CHRISTIAN DEHLENDORFF 2 & SUSANNE K. KJAER 1,5 1 Virus, Lifestyle
More informationEffectiveness of statins in Medicare-eligible patients and patients < 65 years using clinical practice data*
ORIGINAL PAPER Effectiveness of statins in Medicare-eligible patients and patients < 65 years using clinical practice data* K. M. Fox, 1 S. K. Gandhi, 2 R. L. Ohsfeldt, 3 J. W. Blasetto, 4 M. H. Davidson
More informationDiabetes is the most common endocrine
Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Secondary Prevention of Cardiovascular Events With Long-Term Pravastatin in Patients With Diabetes or Impaired Fasting Glucose Results from
More informationSTATINS (3-HYDROXY-3-METHYLglutaryl
ORIGINAL CONTRIBUTION Adherence With Statin Therapy in Elderly Patients With and Without Acute Coronary Syndromes Cynthia A. Jackevicius, BScPhm, MSc, FCSHP Muhammad Mamdani, PharmD, MA, MPH Jack V. Tu,
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationHow to use statins in patients with chronic liver disease
REVIEW CME CREDIT MARK W. RUSSO, MD Center for the Study of Hepatitis C, Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY IRA M. JACOBSON, MD Center for the Study
More informationAre statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in Finland
To cite: Ruokoniemi P, Sund R, Arffman M, et al. Are statin trials in diabetes representative of real-world diabetes care: a populationbased study on statin initiators in Finland. BMJ Open 2014;4:e005402.
More informationSafety profile of atorvastatin-treated patients with low LDL-cholesterol levels
Atherosclerosis 149 (2000) 123 129 www.elsevier.com/locate/atherosclerosis Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels Rebecca G. Bakker-Arkema *, James W. Nawrocki,
More informationSupplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
More informationThis document was created on 07 January 2005 and has been printed from
1 Spontaneous Adverse Event Reporting Information Introduction This document provides information regarding spontaneous adverse event reports received concerning patients taking rosuvastatin, which relates
More informationLipid Management Step Therapy Criteria with Medical Diagnoses Option*
Lipid Management Step Therapy Criteria with Medical Diagnoses Option* * Medical diagnoses are required for implementation of this option. Program may be implemented with the following options: Option One
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationStatins and total (not LDL) cholesterol concentration and outcome of myocardial infarction: results from a meta-analysis and an observational study
Statins and total (not LDL) cholesterol concentration and outcome of myocardial infarction: results from a meta-analysis and an observational study Xia Sheng, Li Wei, Michael J. Murphy, Thomas M. Macdonald
More informationSetting The study setting was secondary care. The economic analysis was conducted in the UK.
Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial Hirsch M, O'Donnell
More information